

Bibliography: William Bains (papers, articles and books)

1. Organisation and expression of cloned histone gene clusters from *Xenopus laevis* and *Xenopus borealis*. R.W.Old, H.R.Woodland, J.E.M.Ballantine, T.C.Aldridge, C.A.Newton, W.A.Bains, P.C.Turner (1982) *Nucl. Acids Res.* 10: 7561-7580
2. Molecular genetics of human myogenesis. Larry Kedes, Helen Blau, Peter Gunning, Phyllis Ponte, Choy-Pik Chiu, William Bains, Joanne Engel and Susan Guttman (1984) *Expl. Med. Biol.* 9: 202-210
3. Cardiac actin is the major actin in skeletal muscle differentiation in vitro. William Bains, Phyllis Ponte, Helen Blau and Larry Kedes (1984) *Mol. Cell. Biol.* 4: 1449-1453
4. MULTAN: a program to align multiple DNA sequences. William Bains (1986) *Nucl. Acids Res.* 14: 159-177
5. Codon usage in histone gene families of higher eukaryotes reflects functional rather than phylogenetic relationships. Dan Wells, William Bains, Larry Kedes (1986) *J. Mol. evol.* 23: 224-241
6. The multiple origins of human alu sequences. William Bains (1986) 23: 189-199
7. Codon distribution in vertebrate genes may be used to predict gene length. William Bains (1987) *J. Mol. Biol.* 197: 379-388
8. Differential patterns of transcript accumulation during human myogenesis. Peter Gunning, Edna Hardeman, Robert Wade, Phyllis Ponte, William Bains, Helen Blau, Larry Kedes (1987) *Mol. Cell. Biol.* 7: 4100-4114
9. Rate of base substitution in mammalian nuclear DNA is dependent on local sequence context. William Bains, Jane Bains (1987). *Mutat. Res.* 179: 65-74
10. Evolutionary paradoxes and natural non-selection. William Bains (1987) *Trends in Biochem Sci.* 12: 90-91
11. Genetic Engineering for Almost Everybody. William Bains. Published Penguin Books (Pelican original) October 1987
12. A novel method for nucleic acid sequence determination. William Bains, Geoff C. Smith (1988) *J. Theor. Biol.* 135: 303-307
13. AXE: a program for isolating short segments of long DNA sequences. William Bains (1988) *Computer appls Biosciences.* 4: 491-492
14. The myth of academic freedom. William Bains (1988) *The Salisbury Review*, December, 33-36
15. Similarity and divergence among rodent repetitive DNA sequences. William Bains, Kay Temple-Smith (1989) *J. Mol. Evol.* 28: 191-199
16. MULTAN(2): a multiple string alignment program for nucleic acids and proteins. William Bains. (1989) *Computer Appl. Biosciences* 5: 51-52
17. The BrAIn Wave. *Electronics Today International*, April 1989, pp12-17
18. Disease, DNA and Diagnosis William Bains (1989). *New Scientist* 6th May, pp48 - 51
19. Reading the genes: a positive prognosis William Bains (1989) *Lloyds Log*, August, pp29 - 31
20. Repetition structure of mammalian nuclear DNA. Frazer Smillie, William Bains (1990) *J. Theor. Biol.* 142: 463-471

21. A program to optimise DNA sequences for protein expression. William Bains (1990) *Computer Applications in the Biosciences* 6: 399 - 400
22. Detection in the 1990s: diagnostic technology in the coming decade. William Bains (1990) *Clinica* Feb. 14th, 15-17
23. Sex and the single micro. William Bains (1990) *BBC Acorn User* June, pp71-73/91-92
24. Watson and the HUGOnaughts. William Bains (1990) *Biotechnology Insight* #82 (June) pp1-2
25. Antisense technology can have substantial impact in several novel application areas. William Bains (1990) *Genetic Engineering News* Nov/Dec, 3, 55
26. Alternative routes through the genome. William Bains (1990) *Bio/Technology* 8:1251-1256
27. Simplified format for DNA probe-based tests. William Bains (1991) *Clin Chem* 37: 248-253
28. Hybridisation methods for DNA sequencing. William Bains (1991) *Genomics* 11: 294-301
29. Antisense in the Fermenter William Bains (1991) *Biotechnology Insight*, Feb., 1-2
30. Mice that would be men. William Bains (1991) *Biotechnology Insight* Feb.
31. Need R&D mean Risk and Doubt. William Bains (1991) *Accountancy*, January, 83-85
32. DNA Sequencing by mass spectrometry. outline of a potential future application. William Bains (1991) *Chimica Oggi*, October, 13-16
33. Antisense RNA as a metabolic tool. William Bains (1991) *Agro Industry Hi-tech* 2:29-31
34. Artificial Intelligence from A to Z. Jenny Raggett and William Bains. Published by Chapman and Hall, Autumn 1991
35. Local sequence dependence of rate of base replacement in mammals. William Bains (1992) *Mutat. Res.* 267: 43-54
36. Characterisation of an unusual human histone H3.3 pseudogene Dan Wells and William Bains (1992) *DNA Sequence* 2: 125-127
37. Sensors for a clean environment. William Bains (1992) *Bio/Technology* 10: 515-518
38. Sequence - so what? William Bains (1992) *Bio/technology* 10: 751-755
39. Setting a sequence to sequence a sequence. William Bains (1992) *Bio/technology* 10: 757-758
40. Local self-similarity of sequence in mammalian nuclear DNA is modulated by a 180bp periodicity. William Bains (1993) *J. Theor. Biol.* 161: 137-143
41. Alignment and comparison of multiple related DNA sequences can be improved by consideration of known patterns of mutation. William Bains (1993) *DNA sequence* 3: 267-276
42. Antisense technology - from cloning to chemistry. William Bains (1993) *Genetic Engineer Biotechnologist.* 13: 117-120
43. Detection of cellular metabolic state using mid-ultraviolet spectrometry. William Bains (1993) *Chimica Oggi* 11: (10) 49-53
44. Codon usage in mammalian genes is biased by sequence slippage mechanisms. William Bains (1993) *DNA sequence* 3: 277-282

45. Detecting toxins and biocides using mid ultraviolet spectrometry. William Bains (1993). Genet. Eng. Biotechnol. 13: 149-159
46. Medical genetics - genes and GPs for the 1990s. William Bains (1993) J. Chem. Tech. Biotechnol. 56: 123-134
47. Characterising and sequencing cDNAs using oligonucleotide hybridisation. William Bains (1993) DNA Sequence 4: 143-150
48. Sensitivity limits of latex agglutination tests. William Bains and Patricia Noble (1993) Amer. Clin. Lab. March, 14-17
49. Mixed hybridisation and conventional strategies for DNA sequencing. William Bains (1993) 10: 84-94
50. Microbial biosensors as environmental alarm systems. William Bains (1993) International Environmental Technology Guide, pub Int. Labmate Ltd., pp35-37
51. Novel Misinformation. William Bains (1993) Bio/Technology, June 1993
52. Bioinformatics in Europe - the federation strikes back. William Bains (1993) Trends in Biotechnology 11: 217-218
53. Biotechnology for pleasure and profit. William Bains (1993) Bio/technology 11: 1243-1247
54. Biotechnology from A to Z. William Bains, Introduction by G. Kirk Rabb. Published by Oxford University Press, April 1993: 2nd edition 1998
55. The Message behind the Movie (review). William Bains (1993) Bio-Technology 11: 756
56. A spectroscopically interrogated flow-through type toxicity biosensor. William Bains (1994) Biosens. Bioelectr. 9: 111-117
57. Selection of oligonucleotide probes and experimental conditions for multiplex hybridisation experiments. William Bains (1994) Genetic Anal.: Techniques and Applications. 11: 49-62
58. Applications of space industry technologies to the life sciences. William Bains (1995) Trends in Biotech. 13: 1-6
59. Use of antisense technology in anti-viral therapy. William Bains (1993) Industrial biotechnology international, pub Sterling Pub., pp43-45
60. The chip of the '90s. William Bains (1995) Chemistry in Britain, Feb., 122-125
61. Bioinformatics - a powerful tool for drug discovery. William Bains (1995), Scrip Magazine, March, 18-19
62. Hybridisation for sequencing of DNA William Bains (1995). in Molecular Biology and Biotechnology, pub VCH, pp441-444
63. Company strategies for bioinformatics. William Bains (1996) Trends in Biotechnology 14: 312-317
64. The cost of delivering drugs without needles. Bob Damms and William Bains (1995) Bio/technology 13: 1438-1440
65. Using bioinformatics in drug discovery. William Bains (1996) Trends in Biotechnology 14: 37-39
66. Virtually sequenced: the next genomic generation. William Bains (1996) Nature Biotechnology 14:711-713
67. Reconstructing the biochemical edifice. William Bains (1996) Nature Biotechnology 14: 928-929
68. Hybridization for sequencing DNA. William Bains (1996) in Encyclopedia of molecular biology and molecular medicine, vol 3, pub VCH 252-260

69. Hexanucleotide frequency database. William Bains (1997) *Computer Appl. Biosciences*.13: 107-108
70. Should you hire an epistemologist? William Bains (1997) *Nature Biotechnology* 15: 396
71. Litigation escalates for patents on a chip. William Bains (1997) *Nature Biotechnology* 15: 406
72. Logical Captain? The science of Star Trek. William Bains (1997) *What Satellite TV* Feb 1997, 56-57
73. The scientist as consultant: building new career opportunities (CJ Sinderman and TK Sawyer). (review) William Bains (1997) *Nature* 390: 136
74. Simple DNA probe assays based on particle agglutination William Bains (1998) *Clinical Chemistry* 44:876-878
75. A simple latex agglutination format for DNA probe-based tests. William Bains (1998) *Analytical Biochemistry* 260: 252-255
76. Genes to proteins in context. William Bains (1998) *Trends in Biotechnology* 16: 2-4
77. Chips and Chimps: The Great Ape genome project? William Bains (1998) *Nature Biotechnology* 16:31
78. Statistical mechanic prediction of non-Gompertzian ageing in extremely aged populations. William Bains (2000) *Mechanisms of Ageing and Development* 112: 89-97
79. New diagnostic technologies: the perspective of the early private institutional investor. William Bains (2000). *Journal of Commercial Biotechnology* 7: 10 - 23
80. The Long-term value of genomics companies. William Bains (2000) *Journal of Chemical Technology and Biotechnology*. 75: 883-900
81. Finding poisons: techniques in gross pollution monitoring. William Bains (2000) in *Towards a collaborative environmental research agenda. Challenges for Business and Society*, ed Alyson Warhurst
82. The Parts List of Life. William Bains (2001) *Nature Biotechnology* 19: 401-402
83. Evolutionary computing methods to predict oral bioavailability QSPRs. William Bains, Richard Gilbert, Lilya Sviridenko, Jose-Miguel Gascon, Robert Scoffin, Kris Birchall, Inman Harvey, John Caldwell (2002) *Current Opinion in Drug Discovery and Development*. 5: 44-51
84. Implications of the network structure of cellular control circuits for the design of anti-cancer vaccine therapies. William Bains (2002). *Medical Hypotheses* 58: 403-410
85. Making late stage decisions early with ADME/Tox prediction. William Bains (2002). *SP2 magazine* June, pp26-28
86. Vasoprotective VEGF as a candidate for prevention of recurrence of fibrotic diseases such as Dupuytren's Contracture. William Bains (2003) *Medical Hypotheses* 60: 793 - 796
87. Silicon Chemistry as a novel source of chemical diversity in drug design. William Bains, Reinhold Tacke (2003). *Current Opinion in Drug Discovery and Development*. 6(4): 526 - 543
88. *Biotechnology from A to Z*. William Bains. Published by Oxford University Press, 3rd edition (1998)

89. Drug Bioavailability, distribution and clearance prediction. William Bains in Encyclopedia of Molecular Cell Biology and Molecular Medicine Vol 3, ed Robert A. Meyers, Wiley-VCH (Weinheim, Germany). pp595 - 638 (2004)
90. Many Chemistries could be used to build living systems. William Bains (2004). *Astrobiology* 4 (2): 137 - 167
91. HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. William Bains, Antranig Basman, Cat White (2004). *Progress in Biophysics and Molecular Biology*. 86: 205 – 233
92. Syntheses and pharmacological properties of the histaminic H1 antagonists sila-terfenadine-A, sile-terfenadine-B, disila-terfenadine, and sila-fexofenadine: a study on C/Si bioisosterism. Reinhold Tacke, Thomas Schmid, Martin Penka, Christian Burschka, William Bains, Julie Warneck. (2004) *Organometallics* 23 (21) 4915 - 4923
93. Paradoxes of Non-Trivial Gene Networks: How Cancer-Causing Mutations Can Appear to Be Cancer-Protective. William Bains (2004) *Rejuvenation Research* 7(3): 199 - 210
94. Failure rates in drug discovery and development: will we ever get any better?" Bains, W. (2004). " *Drug Discovery World* 2004(Fall): 9 - 18.
95. How academics can make (extra) money out of their science. William Bains. *J. Commercial Biotechnology*. 11 (4): 353 - 363
96. σ Ligands of the 1,4'-Silaspiro[tetralin-1,4'-piperidine] Type and the Serotonin/Noradrenaline Reuptake Inhibitor Sila-venlafaxine: Studies on C/Si Bioisosterism. Jürgen O. Daïß, Barbara Müller, Christian Burschka, Reinhold Tacke, William Bains, Julie Warneck. (2005). In *Organosilicon Chemistry VI. From molecules to materials vol 1*. Ed Norbert Auner, Johann Weis. 575 - 581
97. How to write up a hypothesis: the good, the bad and the ugly. William Bains (2005) *Medical Hypotheses* 64 (4): 665-668
98. Fraud and Scandal in Biotech. William Bains, *Nature Biotechnology* 24: (7), 475-476
99. What you give is what you get: investment in European biotech. William Bains, *J. Commercial Biotechnology* 12 (4): 274 - 283
100. Small Company Mergers - good for whom? Vanessa Maybeck and William Bains. *Nature Biotechnology* 24 (11), 1343 - 1348
101. The Timetable of innovation. William Bains *Drug Discovery World*, 2006. 2006(2): p. 3 - 12.